医药医疗行业作为兼具防御性与成长性的长期赛道，其发展始终与人口结构、技术创新、政策导向同频 共振。华商医药医疗行业股票基金经理张晓表示，创新药已从BD叙事转为真正的临床数据叙事，大单 品海外临床数据陆续读出，将继续驱动国内创新药发展；CXO板块今年从订单前瞻来看，拐点或已确 立，持续看好整个产业链的业绩和估值修复。 针对她所管理的华商医药医疗行业股票基金，张晓表示，基金配置重心聚焦于创新产业链，包括创新药 与CXO。她认为，创新药方面，行业逻辑已从BD叙事转为真正的临床数据叙事，大单品海外临床数据 陆续读出，将继续驱动国内创新药发展；CXO板块，从订单前瞻来看，拐点或已确立，持续看好整个 产业链的业绩和估值修复。 数据说明：文中基金经理观点及基金策略信息来自基金定期报告，基金经理关注领域仅代表基金经理作 出的判断，可能随市场情况调整，不代表基金的实际投向，具体投资策略和投资标的详见基金法律文件 及基金定期报告。 截至2025年12月31日，张晓具有10.5年证券从业经历（其中6.3年证券研究经历，4.2年证券投资经 历）。张晓历任基金：华商医药医疗行业股票2022.05.19至今、华商恒益稳混合2025.03 ...

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The market turnover decreased to 82.799 billion HKD, with net inflows of 484 million HKD recorded in the Hong Kong Stock Connect [1] - The US stock market showed mixed results, with the Dow Jones rising 0.1% to a new closing high, while the S&P 500 and Nasdaq fell by 0.33% and 0.59% respectively [2] Sector Performance - In the Hong Kong market, local real estate, software, and 5G sectors saw significant declines, while gold stocks performed well [1] - Biotechnology and cultural media sectors were active, with the Hang Seng Index rising 0.58% and the Hang Seng Technology Index increasing by 0.62% [1] - Notable stock performances included a 5.5% increase for CSPC Pharmaceutical Group and a 15.4% rise for China Literature [1] Investment Opportunities - The report emphasizes the importance of "technological self-reliance" and AI applications as key themes for future growth in the Hong Kong market, suggesting that leading companies in these sectors may benefit from long-term development opportunities [3] - The report recommends focusing on sectors supported by policies aimed at expanding domestic consumption, such as sports apparel and non-essential services [3] - It highlights the value of investing in state-owned enterprises with relatively low valuations and high dividends across various industries [3] Company Highlights - ByteDance's subsidiary Doubao launched a New Year campaign, distributing red envelopes and promoting AI applications, which may boost demand for upstream GPU and AI chips [9] - Innovent Biologics announced a strategic partnership with Eli Lilly, with a total transaction value of up to 8.85 billion USD, indicating strong market confidence in China's innovative drug pipeline [9] - The report suggests monitoring leading companies in the domestic semiconductor foundry industry, such as Hua Hong Semiconductor and SMIC, as they are expected to benefit from favorable policies [9]

Core Views - The A-share market is showing signs of stabilization and recovery, with a positive outlook for the post-holiday market driven by liquidity improvement and policy expectations [2][3][10] - Key sectors such as cultural media, gaming, and AI applications are performing strongly, while sectors like precious metals and new energy are experiencing adjustments [4][9] Market Overview - On Tuesday, the three major indices in the Shanghai and Shenzhen markets showed mixed results, with cultural media and AI application sectors performing well, while precious metals and new energy sectors faced declines [4][5] - The overall market sentiment is characterized by orderly rotation of hotspots, indicating a positive trend towards stabilization [3][9] Sector Analysis - The cultural media sector has shown significant growth, with a 42.75% increase in the first half of 2023, and is expected to continue to have structural investment value in 2026 due to advancements in AI technology and economic recovery [6][7] - The AI theme remains active, with a focus on applications and hardware, indicating a shift from investment in computing power to practical applications in 2026 [7][8] Future Market Outlook - The market is expected to see increased activity post-holiday, with a focus on liquidity return and policy developments, which could provide new investment opportunities [3][10] - Investors are advised to adopt a cautious approach, focusing on low-cost opportunities in small-cap growth stocks and sectors with clear industrial catalysts [3][10]

热点板块： 2月主线仍是科技，但更聚焦基本面景气向上的科技板块。1月市场迎来春季行情的启动，历年春季躁动行情，科技成长方向大概率占 优。2月将是春季行情的延续，主线仍然是科技。但1月经历连续上涨后，部分主题类板块涨幅过大，加之市场流动性有扰动，预计市场将更加聚焦基本面 景气向上的科技板块。关注：1）AI硬件的产业趋势仍然确立，并且主要AI大模型的tokens调用量持续走高。这意味着AI应用的高峰将在2026年出现，继 续关注AI硬件的高增长趋势和AI应用从量变到质变到来的机会。2）半导体国产化仍是大势所趋，关注其中的半导体设备、晶圆制造、半导体材料、IC设 计等。3）新能源材料受益于国内和海外储能需求的快速增长，各环节均出现了一定的供不应求、价格上涨迹象，涨价趋势在2026年将会延续。4）创新药 和CXO经历了近4年的调整后逐步进入收获期，2025年创新药出海迎来高增长和基本面拐点，2026年将延续上行趋势。 窄幅震荡，传媒领涨市场。 在经历了周一的反弹后，周二市场未能延续上涨趋势进入窄幅震荡。各大主要分类指数表现分化，涨跌互现，传媒板块 在seedance催化之下连续第二个交易日领涨市场。近期A股受外盘同步 ...

Market Overview - The Hong Kong stock market opened slightly higher on February 11, with the Hang Seng Index at 27,246.18 points, up 63.03 points, a gain of 0.23% [1] - The Hang Seng Tech Index opened at 5,462.70 points, increasing by 11.67 points, a rise of 0.21% [2] Company Focus - The stock of Zhipu AI (HK02513), referred to as the first large model stock, opened over 4% higher and has accumulated a gain of over 60% this week [3] - Zhipu's core competitive advantages include a fully self-developed technology system, leading model performance, an open-source ecosystem, and deep adaptation to domestic computing power. The company has a high proportion of R&D personnel at 74%, with a core team from Tsinghua KEG Laboratory, showcasing strong academic accumulation in natural language processing [5] - The GLM series has rapidly iterated, with GLM-4.7 performing exceptionally well in programming scenarios. The AutoGLM enables AI to autonomously operate smartphones and computer GUIs, marking a new paradigm in agent technology. Multi-modal capabilities cover text-to-image, text-to-video, and visual understanding, with CogView-4 and CogVideoX ranking highly in open-source evaluations. These technological advantages have been translated into practical applications across various sectors, including technology, finance, government, healthcare, and manufacturing [5] Other Company Updates - Shanghai Xiaonanguo (HK03666) saw a decline of over 16% in early trading. The company announced a strategic restructuring, confirming the temporary suspension of operations for 10 of its Shanghai restaurants. It clarified that claims regarding non-refundable deposits and prepaid cards were incorrect, as it is processing refunds for customers [7] - The market showed mixed performance among tech stocks, with Baidu, Kuaishou, and Bilibili rising over 1%, while Tencent fell over 1%. Innovative drug concept stocks were active, with Zai Lab rising over 3%, and automotive stocks also saw some increases, with BYD up over 1% [7] Market Outlook - CICC's latest view indicates that the recent pullback in the Hong Kong stock market is a result of weak fundamentals, concerns over tightening liquidity, and a decline in the attractiveness of Hong Kong's unique market structure. The overall credit cycle is experiencing turbulence, limiting the market index's potential, with the Hang Seng Index expected to range between 28,000 and 29,000 points [8] - In the short term, the market may have overreacted to various factors, including the nomination of Waller as the next Fed chair and concerns over AI bubbles and the collapse of old technology applications. There may be potential for upward correction after a pullback. In the medium term, a 3% to 4% growth in earnings for Hong Kong stocks is anticipated, which could drive the Hang Seng Index higher [8] - CICC suggests that the main investment focus should follow the direction of credit expansion, particularly in AI technology, cyclical sectors, consumption, and dividends, with AI technology and cyclical sectors being the primary focus of current credit expansion [8]

Market Overview - The market temperature gauge indicates a 75% level, suggesting a strong market sentiment based on the historical P/E ratios of major indices as of February 10, 2026, with the Shanghai Composite Index at 99.59%, Shenzhen Component Index at 92.88%, and ChiNext Index at 50.6% [1]. Sector Performance - The top-performing sectors on February 10, 2026, included Media (+4.27%), Household Appliances (+2.15%), and Computer (+1.11%), while sectors like Coal (-0.84%), Social Services (-1.31%), and Real Estate (-1.40%) faced declines [2][15]. Fund Flows - The sectors with the highest net inflows were Media (¥5.341 billion), Computer (¥0.273 billion), and Social Services (¥0.209 billion). Conversely, the sectors with the largest outflows included Electric Equipment (-¥11.149 billion), Machinery (-¥4.919 billion), and Nonferrous Metals (-¥4.015 billion) [2][15]. ETF Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) rose by 2.90% on February 10, 2026, recovering above the 20-day moving average, driven by the strong performance of the innovative drug sector [5][19]. - The Sci-Tech Innovation Artificial Intelligence ETF (589520) increased by 1.81%, benefiting from the recent advancements in AI technology, particularly the release of the Seedream 5.0 model by ByteDance [7][19]. Investment Insights - Open Source Securities highlighted that China's innovative drug sector is experiencing dual breakthroughs in commercialization and internationalization, suggesting a favorable investment outlook for leading companies in this space [6][19]. - The Sci-Tech Innovation Artificial Intelligence ETF's index components have a significant collaboration with ByteDance, which holds a 29.42% weight in the index as of January 2026, indicating strong growth potential in the AI sector [7][19].

Market Trends - The domestic market indices showed slight fluctuations, with the Shanghai Composite Index closing at 4,128.37, up by 0.13% [4] - During the period from February 2 to February 8, major indices experienced declines, with the Shanghai Composite Index down by 1.27% and the ChiNext Index down by 3.28% [7] Industry Insights - The non-bank financial sector is seeing a revision in underwriting regulatory guidelines, which is expected to enhance investment value in the sector [5] - The media industry is projected to continue its upward trend, driven by AI applications and IP ecosystems, with a 27.17% increase in the media index for 2025 [6] - The power equipment and new energy sector is focusing on the AIDC power revolution, with expectations for a significant increase in photovoltaic power utilization rates [8][19] - The agricultural sector is facing potential price adjustments in pig farming after a peak season, with current prices showing a downward trend [15][17] Company Analysis - Aide Technology is recognized as a leader in domestic spinal vertebral body shaping systems, benefiting from an aging population [22] - Tianfu Communication's 2025 performance forecast indicates a net profit of 1.88 to 2.15 billion yuan, driven by stable demand for optical devices [26] - Wolong Nuclear Materials anticipates a net profit of 1.1 to 1.18 billion yuan for 2025, with strong market demand across various business segments [28] Investment Recommendations - The report suggests focusing on companies that leverage AI applications and IP development, such as Kunlun Wanwei and Shanghai Film [9] - In the photovoltaic sector, companies like Aishuo and Longji Green Energy are recommended due to their technological advancements and market positioning [16][23] - For the copper connection market, companies like Wolong Nuclear Materials are highlighted for their strong growth potential in the telecommunications sector [28]

近期，随着创新药企业陆续披露2025年报及业绩预告，多家企业展现出良好的经营改善态势，在报告期 内实现亏损收窄甚至业绩转正，释放出积极信号。在此背景下，创新药及相关板块再引关注。公告显 示，工银瑞信中证港股通医疗主题交易型开放式指数证券投资基金（简称：港股通医疗ETF工银；代 码：159167）将于2026年2月12日起在深交所上市交易。 公开资料显示，港股通医疗ETF工银（159167）紧密跟踪中证港股通医疗主题指数（代码： 932069.CSI），该指数锚定医疗创新，全面覆盖港股"CXO +互联网医疗+医疗器械+创新药"等医药各领 域核心龙头，并囊括脑机接口、AI医疗、高端医疗器械等热门主题；该指数弹性足，估值具有吸引 力。Wind数据显示，截至2026年2月10日，中证港股通医疗主题指数目前市盈率（TTM）为32.85倍， 处于发布以来48.16%分位，指数当前或未被高估，或仍具有吸引力。 国金证券指出，2025年中国新药License-out交易数量达158笔、总规模1357亿美元，创近十年新高；出 海BD繁荣不仅显著提振短期业绩预期，更推动国产新药国际化开发进程与远期价值提升。申万宏源研 究研报观点 ...

Core Viewpoint - The Hong Kong stock market has experienced volatility recently, but the fundamental outlook and bullish logic remain unchanged, with several positive factors accumulating for the future [1][2]. Group 1: Market Performance - The Hong Kong stock market indices, including the Hang Seng Index and the Hang Seng China Enterprises Index, saw a decline of over 3% in the week from February 2 to February 6, while the Hang Seng Technology Index dropped over 6% [2]. - Following this adjustment, the market rebounded with the indices recording consecutive gains over two trading days as of February 10 [2]. Group 2: Market Drivers - Factors contributing to the recent volatility include a global software sector pullback, controversies surrounding subsidies for Hong Kong tech giants, a rebound in the US dollar, and lingering effects in the commodity market [2]. - Despite the fluctuations, the liquidity in the Hong Kong market remains relatively ample, with significant inflows from foreign and southbound capital [2]. Group 3: Investment Strategy - Investors are advised to maintain a balanced portfolio and hold stocks through the upcoming holiday, focusing on sectors such as semiconductors, innovative pharmaceuticals, leading internet technology companies benefiting from AI trends, and high-dividend stocks with solid fundamentals [1][3]. - The upcoming peak of locked-up shares set to be released from late February to early March may create potential opportunities for market positioning if the market has already adjusted for some selling pressure [2][3].

Group 1 - Seedance2.0 is expected to be a pivotal moment for AI in the film industry, particularly in the production of AI comics and short dramas, leading to significant cost reductions and efficiency improvements in content creation [2] - The release of Seedance2.0 has sparked widespread evaluation and discussion within the industry, showcasing impressive capabilities in multi-modal thinking and video generation from various input types [2] - The film and television sector saw a substantial increase, with the film industry index rising by 13.83%, significantly outperforming other sectors, driven by the excitement around AI applications [2] Group 2 - The innovative pharmaceutical sector is experiencing a resurgence, with notable stock price increases among companies such as Wanbangde and Guangshengtang, indicating renewed investor interest [3] - The National Medical Products Administration announced that by 2025, China's pharmaceutical industry will accelerate its internationalization, with cumulative overseas licensing transactions for innovative drugs expected to exceed $130 billion [3] - A strategic cooperation agreement between Shiyao Group and AstraZeneca could yield up to $18.5 billion, marking a significant milestone in the company's business development transactions [3] Group 3 - Emerging technologies remain a key focus for the market, with a recommendation to concentrate on sectors benefiting from AI applications and international expansion [4] - The recent volatility in the Chinese stock market is attributed to global financial tightening concerns and pre-holiday cautious sentiment, but there is optimism regarding the domestic economic outlook [4] - The semiconductor sales growth is projected to accelerate, with high demand for domestic chips and related industries expected to continue through 2026 [4][5]